Long-term data support tildrakizumab safety, user-friendliness
Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.
Related Articles
New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications
Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis
The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.
Experts Pen 12 Implementable Steps For Addressing Gender Inequity In Academic Dermatology
Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis
The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.
Addressing Research Gaps in the AAD AD Guidelines
David Rosmarin, MD, addresses the research gaps in recommendations for systemic therapies in atopic dermatitis in the latest guidelines.
In Interim Analysis, Mogamulizumab Demonstrates Improvements In Mycosis Fungoides, Sézary Syndrome
Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.
New AAD Atopic Dermatitis Guidelines and Dupilumab Label Updates
Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.
Reviewing the Rosacea Pipeline: A Look at the Last 10 Years
In recognition of Rosacea Awareness Month, Dermatology Times is reviewing research and strides in rosacea treatment over the last decade.
Is Your Texting as Caring as Your Bedside Manner?
Test your knowledge to see if your patients would consider you an efficient texter.
Dermatology Residency Programs Lack Specific, Comprehensive Education on Sensitive Skin
Research from the GW School of Medicine and Health Sciences was recently published in the Journal of Drugs in Dermatology.